Pharmaceutical giant Eli Lilly & Co announced today that their new anti-schizophrenia drug, Zyprexa, is expected to receive approval from the U.S. Food and Drug Administration (FDA) in the coming weeks.
Schizophrenia affects approximately 1% of the global population and is a chronic, debilitating condition characterized by symptoms such as hallucinations, delusions, and disordered thinking and behavior. Currently, there are a limited number of treatment options available for patients with schizophrenia. However, Zyprexa's unique mechanism of action shows promise in treating the symptoms of the disorder.
Eli Lilly & Co's Zyprexa is a second-generation antipsychotic drug that works by blocking dopamine receptors in the brain. This helps to reduce the activity of the neurotransmitter, which is associated with the symptoms of schizophrenia. Zyprexa has been shown in clinical trials to be effective in reducing the severity of symptoms in patients with schizophrenia. Additionally, it has fewer side effects than first-generation antipsychotic medications, such as drowsiness and movement disorders.
The FDA's Advisory Committee on Psychopharmacologic Drugs met last week to review the data presented by Eli Lilly & Co on the safety and efficacy of Zyprexa. The committee voted unanimously in favor of the drug's approval, citing the considerable unmet need for new treatment options for patients with schizophrenia.
"We are pleased with the positive recommendation from the FDA's Advisory Committee," said Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories. "Zyprexa has the potential to be an important new treatment option for patients with schizophrenia, and we look forward to bringing it to market soon."
If approved by the FDA, Zyprexa will be the first new anti-schizophrenia drug to receive approval in over a decade. This would be a significant milestone for Eli Lilly & Co and a promising development for patients suffering from this devastating disorder.